Vascular calcifications: Pathogenesis, management, and impact on clinical outcomes

Journal of the American Society of Nephrology

Volumn 17, Issue SUPPL. 3, 2006, Pages

  Cannata Andía, Jorge B ^a   Rodríguez García, Minerva ^a   Carrillo López, Natalia ^a   Naves Díaz, Manuel ^a   Díaz López, Bernardino ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHATE;

AGE; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FRACTURE; FRAGILITY FRACTURE; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 33845274560     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006080925     Document Type: Conference Paper

References (43)

1. Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS: Soft tissue calcification in chronic dialysis patients. Am J Pathol 86: 403-424, 1977
2. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis JR: Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2: 875-877, 1987
3. Mazzaferro S, Coen G, Bandini S, Borgatti PP, Ciaccheri M, Diacinti D, Ferranti E, Lusenti T, Mancini G, Monducci I, et al.: Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 8: 335-340, 1993
4. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401, 1996
5. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001
7. Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB: Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol 18: 458-463, 2005
8. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
9. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001
10. Goldsmith D, Ritz E, Covic A: Vascular calcification: A stiff challenge for the nephrologist - Does preventing bone disease cause arterial disease? Kidney Int 66: 1315-1333, 2004
11. Ketteler M, Gross ML, Ritz E: Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 94: S120-S127, 2005
12. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44: 1024-1030, 2004
13. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495, 2004
14. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 38[Suppl 1]: S34-S37, 2001
15. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 2511-2516, 2001
16. Shanahan CM: Mechanisms of vascular calcification in renal disease. Clin Nephrol 63: 146-157, 2005
17. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361: 827-833, 2003
18. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357-366, 2003
19. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
20. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17, 2000
21. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
22. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
23. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005
24. Naves M, Guinsburg A, Marelli C, Tejada J, Silvestri F, Passlick-Deetjen J, Cannata-Andia J: Relative risk (RR) of death according to serum Ca, P and PTH. Results from a large sample of dialysis patients from Latin America followed for up to 54 months. The CORES Study [Abstract]. J Am Soc Nephrol 16: 728A, 2005
25. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
26. Naves M, Guinsburg A, Marelli C, Fernandez-Martín JL, Alvarez-Hernandez D, Passlick-Deetjen J, Cannata-Andia J: Oral active vitamin D and hemodialysis (HD) survival in a large cohort from Latin America. The CORES study [Abstract]. J Am Soc Nephrol 2006, in press
27. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998
28. Rodriguez-Garcia M, Gomez Alonso C, Naves Diaz M, Gago E, Cespedes M, Megido J, Forascepi R, Cannata Andia JB: Vascular calcification, bone mass, vertebral fractures ands mortality in haemodialysis patients [Abstract]. J Am Soc Nephrol 15: 175A, 2004
29. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661, 2003
30. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
31. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
32. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Effects of calcitriol and paricalcitol on VSMC proliferation and calcification [Abstract]. J Am Soc Nephrol 16: 496A, 2005
33. Tentori F, Hunt WC, Stidley CA, Rohrschreib MR, Bednick EJ, Meyer KB, Johnson HK, Fager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int October 4, 2006 [epub ahead of print]
34. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96: 1755-1760, 1997
35. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17: 795-804, 2006
36. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C: Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570-578, 2002
37. Kamel HK: Male osteoporosis: New trends in diagnosis and therapy. Drugs Aging 22: 741-748, 2005
38. Mitterbauer C, Schwarz C, Haas M, Oberbauer R: Effects of bisphosphonates on bone loss in the first year after renal transplantation: A meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21: 2275-2281, 2006
39. Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21: 817-824, 2001
40. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H: Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44: 680-688, 2004
41. Roman Garcia P, Naves M, Carrillo Lopez N, Rodriguez Garcia M, Serrano Arias M, Cannata Andia JB: Effect of estrogen on OPG expression in abdominal aorta in rats with chronic kidney disease (CKD) and ovariectomy (OVX) [Abstract]. Nephrol Dial Transplant 21[Suppl 4]: iv407, 2006
42. Naves M, Guinsburg A, Ambrosoni F, Marelli C, Passlick-Deetjen J, Cannata-Andia J: Are the K/DOQI guidelines for bone metabolism useful for predicting and preventing relevant cardiovascular (CV) outcomes in dialysis patients from Latin America? Results from the CORES study [Abstract]. J Am Soc Nephrol 16: 306A, 2005
43. Cannata Andia JB, Carrera F: The consequences of uncontrolled mineral metabolism in chronic kidney disease. A role for the COSMOS study. Nephrol Dial Transplant 2006, in press